Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk.

被引：0
|
作者：
Gattermann, Norbert [1 ]
Sanz, Guillermo F. [2 ]
Giagounidis, Aristoteles [3 ]
Seymour, John F. [4 ]
Fenaux, Pierre [5 ]
Santini, Valeria [6 ]
Mufti, Ghulam J. [7 ]
Muus, Petra [8 ]
Ramos, Fernando [9 ,10 ]
Lucy, Lela M. [11 ]
Beach, C. L. [11 ]
Silverman, Lewis R. [12 ]
机构：
[1] Univ Dusseldorf, Dept Hematol Oncol, Dusseldorf, Germany
[2] Hosp Univ La Fe, Dept Hematol, Valencia, Spain
[3] St Johannes Hosp, Med Klin 2, Duisburg, Germany
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[5] Univ Paris 13, Hop Avicenne, Serv Hematol Clin, Bobigny, France
[6] UF Ematol AOU Careggi, Florence, Italy
[7] Kings Coll Hosp London, London, England
[8] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands
[9] Hosp Leon, Leon, Spain
[10] IBIOMED, Leon, Spain
[11] Celgene Corp, Overland Pk, KS USA
[12] Mt Sinai Sch Med, Div Hematol Oncol, New York, NY USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1643 / 1644
页数：2
相关论文
共 50 条
  • [1] Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study
    Seymour, John F.
    Bennett, John M.
    List, Alan F.
    Mufti, Ghulam J.
    Gore, Steven D.
    Fenaux, Pierre
    Santini, Valeria
    Hetzer, Joel
    Songer, Stephen
    Skikne, Barry S.
    Beach, C. L.
    BLOOD, 2012, 120 (21)
  • [2] Relationship among gene methylation, azacitidine treatment, and survival in patients with higher-risk myelodysplastic syndromes (MDS): results from the AZA-001 trial
    Herman, James G.
    Gore, Steven
    Mufti, Ghulam
    Fenaux, Pierre
    Santini, Valeria
    Silverman, Lewis
    Seymour, John
    Griffiths, Elizabeth
    Caraway, Hetty
    MacBeth, Kyle
    McKenzie, David
    Backstrom, Jay
    Beach, C. L.
    CANCER RESEARCH, 2009, 69
  • [3] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 91 - 91
  • [4] Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission
    List, A. F.
    Fenaux, P.
    Mufti, G. J.
    Hellstroem-Lindberg, E.
    Gore, S.
    Bennett, J. M.
    Silverman, L. R.
    Backstrom, J.
    Allen, A. R.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)
    Seymour, John F.
    Silverman, Lewis R.
    Doehner, Hartmut
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Minden, Mark D.
    Stone, Richard M.
    Lucy, Lela M.
    Songer, Stephen
    Dougherty, Donna
    Hinkle, Randy
    Gambini, Dominique
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2015, 126 (23)
  • [6] Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): Results of the AZA-001 phase III study
    Fenaux, Pierre
    Mufti, G. J.
    Santini, V.
    Finelli, C.
    Giagounidis, A.
    Schoch, R.
    List, A. F.
    Gore, S. D.
    Seymour, J. F.
    Hellstrom-Lindberg, E.
    Bennett, J. M.
    Byrd, J. C.
    Backstrom, J. T.
    Zimmerman, L. S.
    McKenzie, D. R.
    Beach, C. L.
    Silverman, L. R.
    BLOOD, 2007, 110 (11) : 250A - 251A
  • [7] AN EVALUATION OF THE ASSOCIATION OF CDKN2B (P15) DNA METHYLATION WITH RESPONSE AND SURVIVAL IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) TREATED IN THE AZA-001 TRIAL
    Herman, J.
    Mufti, G.
    MacBeth, K.
    Seymour, J.
    Fenaux, P.
    Gore, S.
    Santini, V.
    Lucy, L.
    Beach, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 124 - 124
  • [8] A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
    Gore, Steven D.
    Fenaux, Pierre
    Santini, Valeria
    Bennett, John M.
    Silverman, Lewis R.
    Seymour, John F.
    Hellstrom-Lindberg, Eva
    Swern, Arlene S.
    Beach, Charles. L.
    List, Alan. F.
    HAEMATOLOGICA, 2013, 98 (07) : 1067 - 1072
  • [9] EFFECT OF AZACITIDINE (AZA) ON TRANSFUSION INDEPENDENCE (TI) AND OVERALL SURVIVAL IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Seymour, J.
    Santini, V.
    Fenaux, P.
    Giagounidis, A.
    Sanz, G.
    List, A. F.
    McKenzie, D.
    Backstrom, J.
    Beach, C. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 328 - 328
  • [10] Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial
    Seymour, John F.
    Fenaux, Pierre
    Silverman, Lewis B.
    Mufti, Ghulam J.
    Hellstroem-Lindberg, Eva
    Santini, Valeria
    List, Alan F.
    Gore, Steven D.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 1241 - 1242
12345